Dr Charles Whittaker is an Assistant Professor of Infectious Diseases & Vaccinology at the University of California, Berkeley, where he directs the Pandemic and Epidemic Threat Analytics Lab (PETAL). His group integrates infectious-disease modelling, viral phylodynamics and machine learning to uncover new insights into how pathogens spread through populations and to enhance preparedness and response strategies for public-health emergencies. Before joining Berkeley, Charles was a Sir Henry Wellcome Research Fellow at the MRC Centre for Global Infectious Disease Analysis, Imperial College London, where he co-led a team providing global analytical support to countries around the world during the COVID-19 pandemic. He is also a field epidemiologist, and previously served with both the UK’s Public Health Rapid Support Team and the World Health Organization, the latter including deployment to the 2018–2020 North Kivu Ebola outbreak in the Democratic Republic of the Congo, where he provided real-time modelling support for field operations. His research is built on collaborative partnerships with public-health agencies and scientists across Africa, the Americas, Europe and Asia, and is regularly translated into decision-making tools that guide regional and international health policy.
4 x speaker presentations, 15 minutes each:
1. Overview of broadly protective vaccines for pandemic prevention: A CIDRAP representative on: 1) the limitations of exclusively reactive vaccine development, 2) the value of defining explicit public health use cases to inform vaccine development, and 3) a brief overview of the various use cases applicable to vaccines for pandemic prevention. 2. Vaccine development and preparedness: A CEPI representative (e.g., Nadia Cohen, Adam Hacker, Mandeep Singh Dhingra) on broadly protective vaccines and how the various use cases can complement CEPI’s 100 Days Mission.3. Broadly protective vaccine feasibility: Florian Krammer, Rebecca Cox, Pamela Bjorkman, or a comparable virologist on what degree of breadth and protection is technically achievable vs. what is needed, using influenza and/or coronavirus vaccines as examples.4. Epidemiology, modeling, and deployment: Charles Whittaker, Asra Ghani, Ros Hollingsworth, Jane True, Lin-Fa Wang, or a comparable expert on when vaccination could prevent spillover, outbreak growth, transmission, and severe disease, as well as the potential impact of vaccine hesitancy, especially as it relates to MRNA platforms.
Additionally Proposed Speakers:CIDRAP RepresentativeCEPI Representative - Nadia Cohen, Adam Hacker, Mandeep Singh DhingraVirologist - Florian Krammer, Rebecca Cox, Pamela Bjorkman